Publications
110
Citations
4,175
Est. group size
~2
Recurring co-author estimate
Active years
26
Publishing since 2001
Kamal S. Pohar's work centers on bladder cancer, particularly comparing surgical approaches (radical cystectomy, lymph node removal extent) with bladder-sparing treatments for non-muscle-invasive and muscle-invasive disease. Much of the research involves large multicenter clinical trials and guideline development aimed at improving treatment selection and outcomes for patients with recurrent or high-risk bladder cancer.
Publication output has remained fairly steady over the last decade, with a dip around 2019-2021 followed by a return to 7-8 papers per year from 2022 onward.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
European Urology · 2026
- Abstract 814: Lymphatic exudate is a novel source of tumor-associated immune cells.
Cancer Research · 2026
- PD25-05 PATIENT PREFERENCES, TREATMENT RECEIVED, AND QUALITY OF LIFE IN THE CISTO STUDY COMPARING RADICAL CYSTECTOMY OR BLADDER-SPARING THERAPY FOR RECURRENT HIGH-GRADE NMIBC
The Journal of Urology · 2026
- Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancer
Journal of Clinical Oncology · 2025
- RADICAL CYSTECTOMY VERSUS BLADDER-SPARING THERAPY FOR RECURRENT HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER: RESULTS FROM THE COMPARISON OF INTRAVESICAL THERAPY AND SURGERY AS TREATMENT OPTIONS (CISTO) STUDY
The Journal of Urology · 2025
- Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer
New England Journal of Medicine · 2024
- Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection
European Urology · 2024
- Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer
Translational Cancer Research · 2024
- P2-03 SWOG S1011–SUBGROUP ANALYSIS OF THE PHASE III SURGICAL TRIAL TO EVALUATE THE BENEFIT OF A STANDARD VERSUS AN EXTENDED LYMPHADENECTOMY PERFORMED AT TIME OF RADICAL CYSTECTOMY FOR MUSCLE INVASIVE UROTHELIAL CANCER
The Journal of Urology · 2024
- Interruptions in bladder cancer care during the COVID-19 public health emergency
UNC Libraries · 2024
- A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non–muscle-invasive Bladder Cancer
European Urology Oncology · 2023
- Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer
BMC Cancer · 2023
- Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer
Bladder Cancer · 2023
- Interruptions in bladder cancer care during the COVID-19 public health emergency
Urologic Oncology Seminars and Original Investigations · 2023
- SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.
Journal of Clinical Oncology · 2023
- The Journal of Urology×17
- Urologic Oncology Seminars and Original Investigations×7
- Journal of Clinical Oncology×7
- Journal of the National Comprehensive Cancer Network×5
- Bladder Cancer×3
- Cheryl T. Lee
Medicine · The Ohio State University
- Hristos Z. Kaimakliotis
Medicine · Indiana University
- Cheryl Lee
Medicine · The Ohio State University
- Courtney Yong
Medicine · Indiana University
- Ahmad Shabsigh
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile